News
The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics.
FEATURED STORIES
Even as FDA approvals for biologic therapies fell in the first half of 2026, regulatory experts are optimistic about a turnaround in the rare disease space after the departure of key leaders at the agency. Still, there will continue to be tension between science and politics.
Early-stage financing rounds are on track to hit their lowest dollar value in years as funders continue to eschew risky investments, experts told BioSpace.
A mostly black box since emerging with more than a billion dollars in hand, Xaira Therapeutics is slowly pulling back the curtain, revealing plans to find partners and validate its pipeline.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
While the “speed of science” to develop a successful coronavirus vaccine against the novel COVID-19 has been record-setting, scientists are telling us it’s not enough.
After announcing that the FDA was investigating a possible death associated with its lymphoma drug Ukoniq (umbralisib), things are seemingly looking up for TG Therapeutics.
Kallyope focuses on the gut-brain axis, a bi-directional communication between the gastrointestinal tract and the brain.
Shares of ImmunoGen are climbing this morning after the company announced an antibody drug conjugate (ADCs) collaboration with Eli Lilly valued at up to $1.7 billion.
Terray Therapeutics has generated $60 million from a Series A financing round just shortly after getting $20 million in seed funding for the AI drug discovery.
Robert Califf’s nomination to resume his role as FDA Commissioner continues to advance in the Senate, despite some opposition from a key Democrat, Sen. Joe Manchin.
Bristol Myers Squibb and Exelixis reported two-year follow-up data from the Phase III trial of BMS’s checkpoint inhibitor Opdivo (nivolumab) and Exelixis’ Cabometyx (cabozantinib).
The unspoken challenge is: how diverse can a trial run in the United States really be right now?
The three-year agreement leverages AvantGen’s yeast display technology for antibody discovery optimization to engineering antibodies into Antibody-Drug Conjugate treatments.
The grant is the latest in a steady stream of company advances highlighted by the addition of a chief financial officer in January and several collaborative agreements in the past year.